Schrödinger, Inc.
Financials
Valuation Metrics
Schrödinger, Inc.'s Market Cap is $1.14B. At end of 2025 it was $1.31B. Ranked #2424 of 3,111 in US market (top 78%), #978 of 1,445 on NASDAQ (top 68%), #153 of 206 in Health Care Equipment & Services (top 74%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.14B | US#2,424/3,111 Sec#153/206 |
| Revenue | $255M | US#2,620/3,111 Sec#167/206 |
| Net Income | $-103M | US—/3,111 Sec—/206 |
| Total Assets | $634M | US#2,666/3,111 Sec#152/206 |
| Net Assets | $314M | US#2,527/3,111 Sec#146/206 |
| Employees | 850 | US#1,286/3,111 Sec#104/206 |
| Value | ||
| P/B | 3.64x | US#1,889/3,111 Sec#114/206 |
| P/S | 4.48x | US#2,185/3,111 Sec#154/206 |
| FCF Yield | -12.99% | US—/3,111 Sec—/206 |
| Profitability | ||
| ROE | -33.00% | US#2,642/3,111 Sec#166/206 |
| ROA | -16.32% | US#2,743/3,111 Sec#168/206 |
| Op. Margin | -64.65% | US#2,791/3,111 Sec#191/206 |
| Revenue Growth | -1.62% | US#2,366/3,111 Sec#171/206 |
| Financial Health | ||
| Debt Ratio | 102.26% | US#1,119/3,111 Sec#109/206 |
| Total Debt | $107M | US#2,392/3,111 Sec#134/206 |
| FCF | $-148M | US#2,688/3,111 Sec#197/206 |
| Cash | $260M | US#1,530/3,111 Sec#87/206 |
| Current Ratio | 2.74x | US#898/3,111 Sec#95/206 |
| Dividend | ||
| Div. Yield | 0.00% | US—/3,111 Sec—/206 |
| Payout Ratio | 0.00% | US—/3,111 Sec—/206 |
| Performance | ||
| 1Y Return | -21.76% | US#2,642/3,111 Sec#177/206 |
| 1M Return | -9.48% | US#2,338/3,111 Sec#153/206 |
| From 52W High | -35.66% | US#2,346/3,111 Sec#158/206 |
| 1Y MDD | -57.96% | US#2,671/3,111 Sec#166/206 |
| Trading | ||
| Volume | 968,799 shares | US#1,275/3,111 Sec#77/206 |
| Trading Value | $15M | US#1,986/3,111 Sec#131/206 |
| Per Share | ||
| EPS | $-1.41 | US—/3,111 Sec—/206 |
| BPS | $4.94 | US#2,238/3,111 Sec#142/206 |
Company Info
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.